Table 1.

A Summary of Phase 3 Trials of Brivaracetam as an Adjunctive Therapy for Partial-Onset Seizures in Adults

Study	Design	Population	Group	Number (ITT)	Male Gender (n [%])	Age in Years (mean [SD])	Duration of Epilepsy in Years (mean [SD])	Median Reduction in Baseline-Adjusted POS Frequency per Week (%)
Ryvlin et al. (2014)6 (NCT00490035)	Prospective, multicenter, doubleblind, randomized, placebocontrolled	Patients with uncontrolled focal seizures despite treatment with 1–2 AEDs	Placebo	100	54 (54.0)	36.4 (13.0)	20.4 (12.3)	17.0
			20 mg	99	61 (61.6)	35.7 (12.5)	22.1 (13.6)	30.0 (P = 0.019)
			50 mg	99	54 (54.5)	38.9 (13.6)	22.3 (13.0)	26.8 (P = 0.092)
			100 mg	100	58 (58.0)	38.0 (13.1)	22.1 (12.8)	32.5 (P = 0.004)
Biton et al. (2014)7 (NCT00464269)	Prospective, multicenter, randomized, doubleblind, placebocontrolled, parallelgroup, fixeddose	Patients with wellcharacterized partial epilepsy not fully controlled despite treatment with 1–2 AEDs	Placebo	98	43 (43.9)	37.5 (12.6)	24.3 (12.2)	17.8
			5 mg	97	49 (50.5)	38.9 (11.6)	22.2 (12.1)	20.0
			20 mg	100	52 (52.0)	37.3 (13.3)	22.9 (14.0)	22.5
			50 mg	101	51 (50.5)	38.9 (12.3)	26.2 (12.0)	30.5 (P = 0.003)
Klein et al. (2014)8 (NCT00490035)	Prospective, multicenter, doubleblind, randomized, placebocontrolled	Patients with uncontrolled POS despite ongoing treatment with 1–2 AEDs	Placebo	259	133 (50.9)	39.8 (12.5)	22.7 (13.3)	17.6
			100 mg	252	102 (40.3)	39.1 (13.4)	22.2 (13.3)	37.2 (P < 0.001)
			200 mg	249	133 (53.2)	39.8 (12.8)	23.4 (14.6)	35.6 (P < 0.001)
Kwan et al. (2014)9 (NCT00504881)	Prospective, multicenter, randomized, doubleblind, placebocontrolled, flexible dose	Patients with focal or generalized epilepsy uncontrolled on 1–3 AEDs	Placebo	121	69 (57.0)	36.5 (11.5)	–	18.9
			BRV	359	181 (50.4)	35.6 (11.5)	–	26.9 (P = 0.070)

AEDs = antiepileptic drugs; BRV = brivaracetam; ITT = intention to treat; POS = partialonset seizure; SD = standard deviation.